Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 11/20 | 0.56 |
| ▸ | PLAT | P00750 | 11/20 | 0.56 |
| ▸ | PLG | P00747 | 9/20 | 0.56 |
| ▸ | F2 | P00734 | 9/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NPR3 | P17342 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16143957 | 0.90 | PLAU (0.57) | PLAUPLATPLGF2F10 | |
| SCHEMBL2246858 | 0.87 | F2 (0.61) | PLAUPLATPLGF2F10 | |
| SCHEMBL2249559 | 0.84 | PLAU (0.62) | PLAUPLATPLGF2F10 | |
| SCHEMBL2242822 | 0.79 | PLAU (0.54) | PLAUPLATPLGF2F10 | |
| SCHEMBL29850256 | 0.78 | SMN1; SMN2 (0.41) | CYP3A4CYP2C19 | |
| SCHEMBL2243330 | 0.78 | PLAU (0.77) | PLAUPLATPLGF2F10 | |
| SCHEMBL2246986 | 0.78 | F2 (0.60) | PLAUPLATPLGF2F10 | |
| SCHEMBL2242618 | 0.77 | PLAU (0.56) | PLAUPLATPLGF2F10 | |
| SCHEMBL2242318 | 0.76 | F2 (0.33) | PLAUPLATPLGF2F10 | |
| SCHEMBL16143958 | 0.75 | PLAU (0.61) | PLAUPLATPLGF2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-20080312191-A1 | Novel Urokinase Inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312191-A1 | Novel Urokinase Inhibitors | PLAU, PLAUR, SERPINE1 | PLAU 1/4885PLAT 5/4885PLG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.